|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
90,630,000 |
Market
Cap: |
21.86(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$142.67 - $278.38 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile BeiGene is a commercial-stage biotechnology company focused on developing and commercializing molecularly-targeted and immuno-oncology cancer therapeutics. Co.'s clinical-stage drug candidates include: Zanubrutinib, which is a small molecule inhibitor of Bruton's tyrosine kinase for the treatment of mantle cell lymphoma in adult patients; Tislelizumab, which is a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1; Pamiparib (BGB-290), which is for the treatment of various solid tumors; and Lifirafenib, which is an investigational small molecule inhibitor with RAF monomer and dimer inhibition activities.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
203,452 |
1,421,863 |
20,425,867 |
21,641,969 |
Total Sell Value |
$51,856,153 |
$359,832,086 |
$2,147,483,647 |
$2,147,483,647 |
Total People Sold |
6 |
7 |
9 |
10 |
Total Sell Transactions |
20 |
37 |
53 |
73 |
End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Wang Xiaodong |
Chair, Scientific Advisory Brd |
|
2025-06-24 |
4 |
AS |
$263.50 |
$532,867 |
D/D |
(2,007) |
0 |
|
-10% |
|
Wu Xiaobin |
President and COO |
|
2025-06-23 |
4 |
S |
$260.00 |
$354,380 |
D/D |
(1,363) |
0 |
|
6% |
|
Wang Lai |
Global Head of R&D |
|
2025-06-23 |
4 |
S |
$260.00 |
$267,280 |
D/D |
(1,028) |
0 |
|
6% |
|
Oyler John |
Chief Executive Officer |
|
2025-06-23 |
4 |
S |
$261.57 |
$830,360 |
D/D |
(3,174) |
0 |
|
6% |
|
Oyler John |
Chief Executive Officer |
|
2025-06-17 |
4 |
S |
$256.49 |
$374,473 |
D/D |
(1,460) |
0 |
|
5% |
|
Wang Lai |
Global Head of R&D |
|
2025-06-17 |
4 |
S |
$251.37 |
$118,142 |
D/D |
(470) |
0 |
|
5% |
|
Wu Xiaobin |
President and COO |
|
2025-06-17 |
4 |
S |
$250.87 |
$158,047 |
D/D |
(630) |
0 |
|
5% |
|
Oyler John |
Chief Executive Officer |
|
2025-06-16 |
4 |
S |
$266.05 |
$979,046 |
D/D |
(3,680) |
1,460 |
|
9% |
|
Wang Lai |
Global Head of R&D |
|
2025-06-16 |
4 |
S |
$266.40 |
$313,558 |
D/D |
(1,177) |
470 |
|
9% |
|
Lee Chan Henry |
SVP, General Counsel |
|
2025-06-16 |
4 |
S |
$266.50 |
$112,463 |
D/D |
(422) |
0 |
|
9% |
|
Wu Xiaobin |
President and COO |
|
2025-06-16 |
4 |
S |
$265.47 |
$409,694 |
D/D |
(1,543) |
630 |
|
9% |
|
Ball Titus B. |
Principal Accounting Officer |
|
2025-06-11 |
4 |
S |
$258.36 |
$34,620 |
D/D |
(134) |
0 |
|
8% |
|
Wang Lai |
Global Head of R&D |
|
2025-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
86,359 |
1,058,304 |
|
- |
|
Lee Chan Henry |
SVP, General Counsel |
|
2025-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
46,878 |
283,920 |
|
- |
|
Oyler John |
Chief Executive Officer |
|
2025-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
185,055 |
8,281,841 |
|
- |
|
Ball Titus B. |
Principal Accounting Officer |
|
2025-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
29,601 |
73,983 |
|
- |
|
Rosenberg Aaron |
Chief Financial Officer |
|
2025-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
63,674 |
230,802 |
|
- |
|
Wang Xiaodong |
Chair, Scientific Advisory Brd |
|
2025-06-10 |
4 |
AS |
$261.20 |
$10,975,316 |
D/D |
(41,760) |
0 |
|
-8% |
|
Wang Xiaodong |
Chair, Scientific Advisory Brd |
|
2025-06-10 |
4 |
OE |
$6.50 |
$271,440 |
D/D |
41,760 |
41,760 |
|
- |
|
Wang Xiaodong |
Chair, Scientific Advisory Brd |
|
2025-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
98,696 |
5,180,861 |
|
- |
|
Yi Qingqing |
Director |
|
2025-06-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(29,614) |
27,326 |
|
- |
|
Wu Xiaobin |
President and COO |
|
2025-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
123,370 |
1,274,296 |
|
- |
|
Wu Xiaobin |
President and COO |
|
2025-06-06 |
4 |
S |
$250.74 |
$489,591 |
D/D |
(1,934) |
0 |
|
6% |
|
Oyler John |
Chief Executive Officer |
|
2025-06-06 |
4 |
S |
$250.84 |
$1,295,946 |
D/D |
(5,127) |
0 |
|
6% |
|
Lee Chan Henry |
SVP, General Counsel |
|
2025-06-06 |
4 |
S |
$255.78 |
$179,280 |
D/D |
(700) |
0 |
|
6% |
|
654 Records found
|
|
Page 1 of 27 |
|
|